In order to evaluate the risk of cytomegalovirus (CMV) associated disease after allogeneic stem cell transplantation (SCT), 158 consecutive patients at risk for infection were analyzed. BMT was performed in 101 patients and peripheral blood stem cell transplantation (PBSCT) in 57 patients. CMV antigenemia was found in 57 cases (56%) after BMT and 27 cases (47%) after PBSCT, respectively. CMV antigenemia resistant to a 14-day course of GCV was found in 26 patients (26%) after BMT but in only four patients (7%) after PBSCT (P Ͻ 0.01). Eighteen patients (11%) developed CMV disease, 14 post BMT and four post PBSCT. Lethal CMVrelated interstitial pneumonia (CMV-IP) occurred in 13 cases of whom 12 patients were bone marrow recipients (P = 0.04). The subgroup of seronegative patients with a CMV seropositive donor had a significantly lower risk of developing CMV antigenemia, GCV-resistant CMV antigenemia (P Ͻ 0.01) and CMV-related disease (P = 0.01). In conclusion, the incidence of persistent CMV antigenemia and CMV-IP was significantly reduced when allogeneic transplantation was performed with peripheral blood stem cells instead of bone marrow. These findings suggest that our previous in vitro data on improved immune reconstitution after allogeneic PBSCT as compared to allogeneic BMT have clinical relevance. Bone Marrow Transplantation (2000) 25, 665-672. Keywords: CMV infection; CMV interstitial pneumonia; pp65 antigenemia; BMT; PBSCT; immune reconstitution Cytomegalovirus (CMV)-related disease is one of the most frequent infectious complications after allogeneic stem cell transplantation (SCT).
and/or donor before transplantation. 1, 3 There is still controversy about an increased incidence of CMV infection or CMV-related disease after allogeneic bone marrow transplantation (BMT) with a matched unrelated donor (MUD) instead of an identical sibling donor (ISD). 5, 6 The transmission of CMV infection from seropositive blood products can be neglected since white blood cell filtration is routinely used. 3, 7, 8 Prophylaxis with ganciclovir (GCV) given to all seropositive patients leads to a decreased incidence and severity of CMV infection but this therapeutic option is associated with neutropenia and in consequence bacterial and fungal infections are more frequent in these patients. 9, 10 Pre-emptive therapy based on screening for culture-proven CMV infection, CMV antigenemia by leukocyte expression of pp65 matrix protein, or CMV-DNA by PCR testing reduces the incidence of CMV diseases. [11] [12] [13] [14] [15] [16] [17] [18] [19] Viral load appears to be proportional to CMV antigenemia in the systemic circulation. Thus, CMV antigenemia-triggered preemptive treatment lowers the duration and side-effects of antiviral therapy after SCT which is considered to be a significant advantage. [20] [21] [22] With the use of allogeneic peripheral blood stem cells a promising alternative hematopoietic graft has entered the field of clinical SCT. 23 Recently, in vitro studies demonstrated faster immune reconstitution after allogeneic peripheral blood stem cell transplantation (PBSCT) compared to BMT. 24, 25 In consequence, it can be expected that better immune reconstitution against CMV will lead to a reduced CMV-related morbidity and mortality after allogeneic PBSCT. To date, there are few reports on clinical CMV infection or asymptomatic CMV replication after allogeneic PBSCT and interpretation of results is difficult because of a small patient cohort 26 and heterogeneously treated patients form a multicenter survey. 27 In contrast, our patients were homogeneously screened and treated for CMV during the study period. Our main aim was to record whether or not the different sources of hematopoietic stem cells (BMT or PBSCT) exert an influence on the role of CMV-related disease.
Patients and methods

Patients
We present a cohort of 158 patients undergoing first allogeneic BMT or PBSCT between October 1994 and August 1997. Patients were considered to be at risk of CMV infection if either the recipient and/or the donor had positive pre-transplant serology for CMV (CMV IgG positive by ELISA). The cohort included 101 allogeneic BMT and 57 rhG-CSF (Neupogen; Amgen-Roche, München, Germany) primed allogeneic PBSCT. Thirty-four patients were seropositive with a seronegative donor (R+/D−), 76 patients were seropositive with a seropositive donor (R+/D+) and 48 patients were seronegative with a seropositive donor (R−/D+). Patient characteristics according to the different stem cell sources are described in Table 1 . Concerning PBSCT, all patients would have been considered eligible candidates for conventional BMT. However, PBSCT was preferred in situations such as HLA disparities between recipient and family donor, prolonged exposure to interferon alpha in patients with chronic myelogenous leukemia, advanced disease stage, a history of a documented serious infectious complication within 4 months before transplantation, myelodysplastic syndrome, or disability of the donor precluding general anesthesia and conventional marrow harvest. 23 RhG-CSF priming was initiated 4 days before the NS = non-significant; ISD = identical sibling donor; MM = mismatched related donor; MUD = matched unrelated donor; cGVHD = chronic graft-versushost disease; aGVHD = acute graft-versus-host disease; CML = chronic myeloid leukemia; AML = acute myeloid leukemia; ALL = acute lymphocytic leukemia; MDS = myelodysplasia; 1.CP = first chronic phase; AD = advanced disease; 1.CR = first complete remission.
prospective first day of leukapheresis. Doses of rhG-CSF ranged between 5 and 16 g/kg of the donor lean body weight (BW) per day given in one or two daily subcutaneous fractions. The majority of apheresis procedures were performed using a continuous flow blood cell separator (Cobe Spectra; Cobe Inc, München, Germany).
Anti-infectious prophylaxis
All blood products were filtered with leucodepletion filters (PALL Inc, Dreieich, Germany 
GVHD prophylaxis
Prophylaxis against aGVHD included cyclosporin A (CsA) in all cases starting on day −1 at 3 mg/kg in continuous i.v. infusion, monitored regularly. The majority of the 135 patients received short-course methotrexate (MTX). Prednisolone (PDN) instead of MTX was given to eight patients, and 15 patients had CsA as prophylaxis only. All patients were isolated in HEPA rooms. Total decontamination of the gut was as described above unless therapy for aGVHD was required. In the absence of aGVHD decontamination was continued for at least 35 days after SCT.
CMV screening and therapy
After engraftment (WBC Ͼ1 × 10 9 /l), CMV was routinely sought by at least weekly screening for CMV-related matrix protein pp65 antigenemia on inpatients. Outpatients were screened on every follow-up. CMV antigenemia was treated with GCV (Cymeven; Hoffmann La Roche, Grenzbach Wyhlen, Germany) 5 mg/kg twice daily i.v. as pre-emptive therapy. This was continued for at least 14 days if CMV antigenemia resolved. Patients who did not clear the antigenemia within a 14 day course of intravenous GCV were considered to be persistent and treatment was continued. In some cases, the dose of GCV was adjusted to renal function.
CMV antigenemia assay
Polymorphonuclear leukocytes (PMNLs) were isolated from 3 ml of EDTA-treated venous blood by dextran (5%) sedimentation. Contaminating erythrocytes were lysed with ammonium chloride solution. Leukocytes were applied by cytocentrifugation (5 min, 250 g) to uncoated Teflonmasked glass slides. Cells were air-dried overnight and fixed with acetone for 90 s at 4°C. For staining, 50 l of 'CMV-vue' monoclonal antibody cocktail containing clones C 10 and C 11 (Incstar; Stillwater, USA) were added for 45 min at room temperature in a humid chamber. After two washes with phosphate-buffered saline, cells were incubated for 30 min at room temperature with a total of 50 l of prediluted rabbit anti-mouse immunoglobulin (DAKO, Glostrup, Denmark). Finally, 50 l of prediluted APAAP complex (DAKO) were added for 45 min at room temperature, followed by 50 l of chromogenic substrate (DAKO, 25 min, room temperature). Slides were counterstained with hematoxylin and examined at × 250 magnification. A positive result was viewed as brown or redbrown nuclear or perinuclear staining within PMNLs.
CMV culture
Prior to conventional CMV culture, specimens were centrifuged (4°C, 30 min, 8000 g) and the supernatant was passed Bone Marrow Transplantation through 0.45 m filters. The filtered supernatant was used to inoculate roller tubes containing confluent monolayers of fibroblasts. After 1 h of adsorption at 37°C, minimal essential medium supplemented with 2% fetal calf serum was added. Cultures were then incubated at 37°C in a roller drum and examined for cytopathic effects every second day for at least 15 days. Culture medium was replaced 24 h after inoculation of the specimens and weekly thereafter.
CMV disease
CMV pneumonia was diagnosed based on dyspnea, interstitial infiltrates on chest X-ray, a positive CMV culture from bronchial washings, or a proven histologic demonstration in a tissue specimen. Diagnosis of CMV enteritis was based on endoscopic signs of bowel inflammation and histologic demonstration of CMV inclusions, positive in situ hybridation assay, or positive culture for CMV from tissue sample.
Statistical evaluation
Initial exploratory analysis was performed using the chisquare test or Fisher's exact test (for small expected frequencies) to compare proportions of events between subgroups. A Cox proportional hazard regression model was performed adjusting for effects that turned out to be significant in univariate analysis. A stepwise variable selection procedure was used with a cut off level at 0.05 for inclusion of values which had proven significant in the initial exploratory model. Analysis were performed using the SPSS statistical program for Windows, version 8.0.
Results
One hundred and fifty-eight patients at risk of CMV infection after allogeneic SCT were studied. One hundred and one patients (64%) received BMT and 57 (36%) PBSCT. The incidence of aGVHD after BMT and PBSCT was not significantly different. Table 2 provides data on the incidence of CMV reactivation and CMV disease after BMT and PBSCT according to the recipient donor relation of CMV serology before transplantation. Table 3 provides results of multivariate analysis of suspected CMV diseaserelated risk factors as correlated to pp65 antigenemia, persistent pp65 antigenemia, CMV-IgM conversion, CMV disease, and CMV-IP.
CMV antigenemia
CMV antigenemia was detected in a total of 84 cases (53%). The median period of time to detecting CMV antigenemia in 57 patients (56%) after BMT and 27 patients (47%) after PBSCT was 47 days (range, 17-180) and 39 days (range, 16-906), respectively. The subgroup of CMV seronegative patients with seropositive donors had a significantly lower risk of developing CMV antigenemia compared with seropositive recipients on univariate and multivariate analysis (P Ͻ 0.01) (Figure 1 ). 
Persistent CMV antigenemia
Seventy-nine of 84 cases with pp65 antigenemia received GCV treatment for at least 14 days and their response to antiviral treatment was evaluable. Twenty-six episodes of persistent CMV antigenemia were observed after BMT, whereas only four resistant cases occurred after PBSCT (Table 2, Figure 2 ). The median time period to detecting persistent antigenemia was 55 days (range, matched family donors (MM) and MUD and aGVHD grade II-IV were correlated with persistent CMV antigenemia. In contrast, CMV seronegative recipients and patients developing CMV IgM seroconversion had a reduced risk of persistent pp65 antigenemia. Cox regression confirmed that aGVHD II-IV (P Ͻ 0.01), marrow as stem cell source (P = 0.04), and MM and MUD (P Ͻ 0.01) were variables associated with persistent CMV antigenemia. Comparing BMT to PBSCT for persistent CMV antigenemia in the R+/D+ group again, a reduced incidence after PBSCT was found (P = 0.024). Testing MM and MUD separately as covariates for persistent CMV antigenemia in Cox regression, MM was significant (P Ͻ 0.01) but MUD was not (P = 0.07).
IgM seroconversion
Twenty-five percent (39/158) of the patients studied developed CMV-IgM. It was associated with the appearance of CMV pp65 antigenemia (P Ͻ 0.01) since only seven patients showed CMV-IgM seroconversion without prior pp65 antigenemia. In 24 patients (24%) IgM seroconversion was found post BMT and in 15 patients (26%) post PBSCT. Median of time to CMV-IgM detection was 92 days (range, 52-616) after BMT and 98 days (range, 53-525) after PBSCT, respectively. In the majority of cases, CMV IgM seroconversion occurred after pp65 antigenemia with a median interval between onset of antigenemia and seroconversion of 35 days after BMT and 57 days after PBSCT. In two bone marrow recipients IgM seroconv-ersion was found 53 and 103 days before pp65 antigenemia occurred. Seronegative recipients had the lowest risk of CMV-IgM seroconversion on univariate and multivariate analysis (P Ͻ 0.01). Seropositive recipients showed seroconversion in 35% of cases (12/34) if grafted with seronegative donors and in 33% (25/76) if grafted from seropositive donors.
CMV disease
CMV disease developed in 18 cases. After BMT, CMV disease was diagnosed in 14 cases (14%) with 12 cases of CMV-IP which was always a lethal complication. However, after PBSCT, CMV disease occurred in only four patients (7%), including one patient (2%) with CMV-IP. CMV enteritis was diagnosed in five BMT and three PBSCT patients and CMV-esophagitis in one BMT and one PBSCT recipient, respectively. In one BMT patient CMV hepatitis was diagnosed.
Onset of CMV disease and CMV-IP was at a median interval of 63.5 days (range, 42-193) after BMT. After PBSCT, CMV disease was diagnosed at a median interval of 66 days (range, 27-72) with one case of CMV-IP on day 69 after transplantation. One patient developed CMV-IP after BMT without pp65 expression. In this case no specific assay including PCR established the diagnosis allowing initiation of pre-emptive therapy prior to disease manifestation. Thus, empiric treatment was started when interstitial changes were present on chest X-ray. Autopsy confirmed the diagnosis retrospectively.
On univarate analysis, age older than 40 years and aGVHD II-IV were significant factors associated with CMV disease. Recipient CMV seronegativity was protective against CMV disease. CMV-IP was associated with BMT, age over 40 years and aGVHD. The proportion of patients with detectable CMV IgM antibodies, who developed CMV disease and CMV-IP did not differ from those without disease manifestation (P = 0.56 for CMV disease and P = 0.2 for CMV-IP). On multivariate analysis, CMV disease was associated with age over 40 years (P = 0.02) and aGVHD II-IV (P Ͻ 0.01). CMV-IP was correlated with marrow as the stem cell source (P = 0.04) and recipient age over 40 years (P = 0.04). 
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Discussion
To our knowledge this is the first study comparing CMV infection in recipients of unmanipulated allogeneic peripheral blood stem cells and allogeneic bone marrow proving an advantage for PBSCT. A major finding is that despite a similar rate of CMV reactivation in BMT and PBSCT recipients, the risk of persistent CMV antigenemia is significantly reduced in recipients of PBSCT. This could be confirmed by multivariate analysis where aGVHD grade II-IV, MUD or MM, and bone marrow as stem cell source were risk factors for persisting antigenemia. Further, a higher rate of pp65 persistence resulted in a higher rate of lethal CMV-IP in bone marrow recipients. Only one of 13 cases of CMV-IP occurred after PBSCT. On multivariate analysis, recipients over 40 years of age and bone marrow as stem cell source were the two risk factors predictive for CMV-IP.
There are two former studies reporting results on CMV reactivation and CMV disease in patients after allogeneic PBSCT. A multicenter questionnaire found a low incidence of severe CMV infection after allogeneic PBSCT but this study included patients having CD34
+ selection. 27 By contrast, the second study reported a higher risk of CMV infection in recipients of allogeneic PBSCT. 26 This study was based on a smaller patient cohort and included cases with partially T cell-depleted grafts. From previous studies it is well known that besides aGVHD and HLA disparity, recipients of T cell depleted marrow are prone to an increased risk for early and treatment resistant CMV disease. 11, 28, 29 One of the initial major concerns about the clinical application of unmanipulated allogeneic PBSCT was the substantially higher T cell count. PBSCT contains a 1 to 2 log 10 higher number of donor T cells. The higher T cell count may increase the frequency and/or severity of aGVHD, escalating the risk of CMV disease. Despite these concerns, the first reports on larger patient cohorts indicated that PBSCT could be performed without an elevated incidence of aGVHD. 23, 30, 31 Of interest are in vitro studies demonstrating faster immune recovery after allogeneic PBSCT compared to BMT. 24, 25 Our clinical findings on CMVrelated problems provide evidence for a better host defense and a faster immune recovery against CMV-related disease after PBSCT. These results need to be confirmed by other studies but suggest that late infective complications may be reduced following PBSCT.
Besides the influence of the stem cell source in allogeneic transplantation we studied the classic risk factors for CMV disease in our patient cohort. CMV seropositivity of the recipient prior to transplantation constitutes the strongest covariate in multivariate analysis for antigenemia, persisting antigenemia, CMV-IgM seroconversion, CMV associated disease, and CMV-IP. Only 19% of seronegative recipients transplanted with a seropositive donor developed CMV antigenemia. Neither persistent CMV antigenemia nor CMV-IP occurred in any of these patients. In the PBSCT group we found twice as many seronegative recipients receiving grafts from a seropositive donor. This fact probably reduces the global incidence of CMV-related problems in this group. However, using multivariate analysis we confirm that following PBSCT the incidence of per-sistent CMV antigenemia and lethal CMV-IP remains significantly reduced. Also, analyzing the subgroup containing seropositive recipients with seropositive donors we confirm the decreased incidence of persistent CMV antigenemia after PBSCT.
By comparing these data with early results from the Seattle group, 1 it is of interest that seropositive recipients had exactly the same ratio of CMV infection as shown in our cohort (68%), whereas seronegative recipients with a seropositive donor had a three times higher risk of infection (57%) than our patients. These differences in CMV transmission rate are most probably due to changes in transfusion policy that have been introduced during the last decade in order to prevent transfusion-acquired CMV infection. Use of CMV seronegative blood products and routine deleukocytation has reduced the risk of CMV transmission by transfusion. 7 Thus, the risk of CMV transmission in CMV seronegative recipients receiving a CMV seropositive graft and therefore CMV-associated disease is very low. The infectious risk can be restricted to the viral load of the transplant. It is of interest that three out of 25 (12%) CMV negative bone marrow and six out of 23 (26%) CMV negative peripheral blood stem cell recipients developed CMV antigenemia if transplanted with a CMV seropositive donor. Thus, it could be speculated that the higher viral burden of CMV positive peripheral stem cells generate a higher rate of CMV antigenemia without increasing the incidence of further infectious complications. However, this difference did not reach statistical significance in our analysis.
We confirmed that aGVHD grade II-IV was the second strongest independent risk factor for developing persistent antigenemia and CMV-disease after recipient CMV seropositivity. The precise mechanism for the effect of aGVHD on the development of CMV-associated disease remains unknown. CMV-specific cytotoxic T-lymphocytes (CTL) are considered to play an important role in the control of CMV infection. It has been reported that growth of CTL is impaired in patients developing aGVHD. 32 In the presence of aGVHD, CTL growth inhibition as well as the immunosuppressive treatment of aGVHD may result in the reactivation of CMV.
HLA-mismatched family donors or matched unrelated donors were identified as a third independent risk factor for persistent antigenemia. This finding was in accordance with a recently published study from Japan which reported an increased incidence of CMV infection and CMV-associated disease after allogeneic BMT from unrelated donors. 5 Takenaka et al 5 observed that CMV antigen-positive cells did not disappear rapidly after GCV treatment in unrelated donor patients, as compared with HLA-identical sibling donor transplant patients. This group concluded that host immunocompetence is profoundly suppressed in unrelated donor transplant patients compared to recipients of HLAidentical sibling bone marrow. In contrast, a study from a pediatric BMT unit did not show any difference in the incidence of CMV infection between recipients of related and unrelated donor BMT during a study period lasting 7 years. 6 During this study period, not only did the policy of CMV screening change substantially with the introduction of pre-emptive CMV therapy 4 years after starting but more MUD transplants were performed in the second half of the study with T cell depletion in most cases. Thus, interpretation of the results is difficult.
In vivo and in vitro studies have revealed that alloantigenic stimulation facilitates reactivation of CMV from lymphocytes. [33] [34] [35] These observations suggest that alloantigen stimulation by unknown or minor histocompatibility antigens may be another important factor affecting the incidence of CMV infection and CMV-associated disease in MM or MUD SCT. Theoretically, donor T cells from genotypically non-identical donors are insufficient to eliminate CMV from host cells because of the incomplete CMV-HLA antigen recognition due to HLA disparity.
In our cohort there is no difference in HLA matching between the BMT and PBSCT arm when MM and MUD are considered as HLA disparities. Patients undergoing PBSCT were preferentially transplanted from a MM. If no HLA-identical family donor was available BMT was undertaken with a MUD. The disproportion in the study arms was essentially due to the fact that family donors accepted steady-state G-CSF mobilization to provide peripheral blood stem cells, whereas the majority of matched unrelated donors undertook bone marrow donation during the study period only. On multivariate analysis, testing MM and MUD as separate covariates, persistent CMV antigenemia correlated even more strongly with MM than with MUD. This finding should favor the BMT group by showing a better response to GCV therapy, as well as a reduced incidence of CMV-IP. However because of the imbalance in the distribution of MM and MUD, further analysis should be considered. In contrast, our results concerning CMVrelated disease indicate that PBSCT decreases CMV-related problems. However, the overall incidence of aGVHD as clinical manifestation of HLA incompatibility was identical following BMT and PBSCT. Thus, distribution of HLA disparity should be considered to be balanced in the two transplant groups.
Early studies from Seattle 1 identified age as an independent risk factor for CMV excretion. A more recent analysis from Genoa 11 supported theses findings by showing that pp65 antigenemia was significantly increased in older patients. In this cohort, advanced age figured not as a risk factor for pp65 antigenemia, persistent antigenemia, and CMV-IgM conversion but was disclosed as an independent risk factor for CMV-IP on multivariate analysis. As the pathogenesis of CMV-IP depends on multiple factors, one hypothesis of an increased ratio of CMV-IP in older patients is that despite a similar rate of reactivation older patients suffer more from conditioning-induced pulmonary toxicity.
Detection of CMV antigenemia by expression of pp65 lower matrix protein on PMNLs has been proven to be a valuable diagnostic tool. [11] [12] [13] [14] 17, 18 Alternatively, CMV screening by PCR methods has been performed. 15, 22 It seems that PCR methods are analytically too sensitive.
Only those patients who developed CMV disease had evidence of CMV antigenemia in addition to CMV-DNA replication by PCR. 15, 16, 36 For this reason we used CMV antigenemia as an indication for starting GCV therapy thus exposing a smaller number of patients to GCV-related myelotoxicity than would pre-emptive treatment based on PCR testing. In our cohort, the rate of CMV-IP was 8% using pp65 for CMV screening which compares favorably with reports of other groups describing the same method. 5, 11 Future studies are needed to clarify whether quantification of CMV antigenemia and pre-emptive CMV treatment starting at a certain threshold of pp65 antigenemia will further reduce the number of patients who are exposed to ganciclovir treatment without increasing the rate of CMV disease.
